{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T16:43:47Z","timestamp":1775666627891,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,3,23]],"date-time":"2019-03-23T00:00:00Z","timestamp":1553299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,3,23]],"date-time":"2019-03-23T00:00:00Z","timestamp":1553299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Mundipharma (China) Pharmaceutical Co., Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2019,4,1]]},"DOI":"10.1007\/s11523-019-00630-y","type":"journal-article","created":{"date-parts":[[2019,3,23]],"date-time":"2019-03-23T02:03:51Z","timestamp":1553306631000},"page":"149-158","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study"],"prefix":"10.1007","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct03349333","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Xiaonan","family":"Hong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqin","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiqiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huilai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Ke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuankai","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guodong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Liebscher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunxiao","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,23]]},"reference":[{"issue":"3","key":"630_CR1","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s12185-014-1520-3","volume":"99","author":"S Park","year":"2014","unstructured":"Park S, Ko YH. Peripheral T cell lymphoma in Asia. Int J Hematol. 2014;99(3):227\u201339.","journal-title":"Int J Hematol."},{"issue":"20","key":"630_CR2","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375\u201390.","journal-title":"Blood."},{"issue":"3","key":"630_CR3","first-page":"10","volume":"11","author":"KJ Savage","year":"2012","unstructured":"Savage KJ, Reiman T. Peripheral T-cell lymphoms: progress and challenges. Oncol Exch. 2012;11(3):10\u20138.","journal-title":"Oncol Exch."},{"issue":"25","key":"630_CR4","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D, International TCLP. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124\u201330.","journal-title":"J Clin Oncol."},{"issue":"3","key":"630_CR5","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1309\/AJCP7YLTQPUSDQ5C","volume":"138","author":"J Sun","year":"2012","unstructured":"Sun J, Yang Q, Lu Z, et al. Distribution of lymphoid neoplasms in China: analysis of 4638 cases according to the World Health Organization classification. Am J Clin Pathol. 2012;138(3):429\u201334.","journal-title":"Am J Clin Pathol."},{"key":"630_CR6","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1746-1596-6-77","volume":"6","author":"QP Yang","year":"2011","unstructured":"Yang QP, Zhang WY, Yu JB, et al. Subtype distribution of lymphomas in Southwest China: analysis of 6382 cases using WHO classification in a single institution. Diagn Pathol. 2011;6:77.","journal-title":"Diagn Pathol."},{"key":"630_CR7","doi-asserted-by":"publisher","first-page":"623924","DOI":"10.5402\/2011\/623924","volume":"2011","author":"AN Abouyabis","year":"2011","unstructured":"Abouyabis AN, Shenoy PJ, Sinha R, Flowers CR, Lechowicz MJ. A systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma. ISRN Hematol. 2011;2011:623924.","journal-title":"ISRN Hematol."},{"issue":"Suppl 5","key":"630_CR8","doi-asserted-by":"publisher","first-page":"v108","DOI":"10.1093\/annonc\/mdv201","volume":"26","author":"F d\u2019Amore","year":"2015","unstructured":"d\u2019Amore F, Gaulard P, Trumper L, et al. Peripheral T-cell lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v108\u201315.","journal-title":"Ann Oncol."},{"issue":"2","key":"630_CR9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.6004\/jnccn.2018.0007","volume":"16","author":"SM Horwitz","year":"2018","unstructured":"Horwitz SM, Ansell SM, Ai WZ, et al. NCCN guidelines insights: T-cell lymphomas, version 2.2018. J Natl Compr Canc Netw. 2018;16(2):123\u201335.","journal-title":"J Natl Compr Canc Netw"},{"key":"630_CR10","unstructured":"National Comprehensive Cancer Network (2018) NCCN clinical practice guidelines: T-cell lymphomas (version 4.2018). 2018. https:\/\/www.nccn.org\/professionals\/physician_gls\/default.aspx. Accessed July 2018."},{"key":"630_CR11","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","volume":"393","author":"S Horwitz","year":"2019","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393:229\u201340.","journal-title":"Lancet."},{"key":"630_CR12","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.12688\/f1000research.12573.1","volume":"6","author":"JH Yi","year":"2017","unstructured":"Yi JH, Kim SJ, Kim WS. Recent advances in understanding and managing T-cell lymphoma. F1000Res. 2017;6:2123.","journal-title":"F1000Res"},{"issue":"4","key":"630_CR13","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s12185-018-2404-8","volume":"107","author":"Y Shi","year":"2018","unstructured":"Shi Y. Current status and progress of lymphoma management in China. Int J Hematol. 2018;107(4):405\u201312.","journal-title":"Int J Hematol."},{"issue":"10","key":"630_CR14","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","volume":"124","author":"F Ellin","year":"2014","unstructured":"Ellin F, Landstrom J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood. 2014;124(10):1570\u20137.","journal-title":"Blood."},{"issue":"20","key":"630_CR15","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","volume":"123","author":"SM Horwitz","year":"2014","unstructured":"Horwitz SM, Advani RH, Bartlett NL, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014;123(20):3095\u2013100.","journal-title":"Blood."},{"issue":"23","key":"630_CR16","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","volume":"33","author":"OA O\u2019Connor","year":"2015","unstructured":"O\u2019Connor OA, Horwitz S, Masszi T, et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol. 2015;33(23):2492\u20139.","journal-title":"J Clin Oncol."},{"key":"630_CR17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13045-016-0243-8","volume":"9","author":"F Foss","year":"2016","unstructured":"Foss F, Horwitz S, Pro B, et al. Romidepsin for the treatment of relapsed\/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial. J Hematol Oncol. 2016;9:22.","journal-title":"J Hematol Oncol."},{"issue":"8","key":"630_CR18","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","volume":"26","author":"Y Shi","year":"2015","unstructured":"Shi Y, Dong M, Hong X, et al. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol. 2015;26(8):1766\u201371.","journal-title":"Ann Oncol."},{"issue":"1","key":"630_CR19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13045-017-0439-6","volume":"10","author":"Y Shi","year":"2017","unstructured":"Shi Y, Jia B, Xu W, et al. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. J Hematol Oncol. 2017;10(1):69.","journal-title":"J Hematol Oncol."},{"issue":"24","key":"630_CR20","doi-asserted-by":"publisher","first-page":"6657","DOI":"10.1158\/1078-0432.CCR-12-2251","volume":"19","author":"E Marchi","year":"2013","unstructured":"Marchi E, Mangone M, Zullo K, O\u2019Connor OA. Pralatrexate pharmacology and clinical development. Clin Cancer Res. 2013;19(24):6657\u201361.","journal-title":"Clin Cancer Res."},{"issue":"9","key":"630_CR21","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","volume":"29","author":"OA O\u2019Connor","year":"2011","unstructured":"O\u2019Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29(9):1182\u20139.","journal-title":"J Clin Oncol."},{"issue":"10","key":"630_CR22","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1111\/cas.13340","volume":"108","author":"D Maruyama","year":"2017","unstructured":"Maruyama D, Nagai H, Maeda Y, et al. Phase I\/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma. Cancer Sci. 2017;108(10):2061\u20138.","journal-title":"Cancer Sci."},{"key":"630_CR23","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2008.","edition":"4"},{"issue":"4","key":"630_CR24","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17(4):1244.","journal-title":"J Clin Oncol"},{"issue":"9","key":"630_CR25","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1200\/JCO.2015.63.5540","volume":"34","author":"SV Adams","year":"2016","unstructured":"Adams SV, Newcomb PA, Shustov AR. Racial patterns of peripheral T-cell lymphoma incidence and survival in the United States. J Clin Oncol. 2016;34(9):963\u201371.","journal-title":"J Clin Oncol."},{"issue":"16","key":"630_CR26","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","volume":"31","author":"V Mak","year":"2013","unstructured":"Mak V, Hamm J, Chhanabhai M, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol. 2013;31(16):1970\u20136.","journal-title":"J Clin Oncol."},{"issue":"7","key":"630_CR27","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.3324\/haematol.2017.186577","volume":"103","author":"M Bellei","year":"2018","unstructured":"Bellei M, Foss FM, Shustov AR, et al. The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, international T-cell project. Haematologica. 2018;103(7):1191\u20137.","journal-title":"Haematologica."},{"key":"630_CR28","unstructured":"Allos Therapeutics Inc. Folotyn prescribing information. 2016. http:\/\/www.folotyn.com\/HCP\/downloads\/folotyn-pi_Nov2016.pdf. Accessed July 2018."},{"key":"630_CR29","doi-asserted-by":"publisher","first-page":"354","DOI":"10.3389\/fphar.2017.00354","volume":"8","author":"M Cinausero","year":"2017","unstructured":"Cinausero M, Aprile G, Ermacora P, et al. New frontiers in the pathobiology and treatment of cancer regimen-related mucosal Injury. Front Pharmacol. 2017;8:354.","journal-title":"Front Pharmacol."}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-019-00630-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-019-00630-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-019-00630-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T12:01:13Z","timestamp":1628596873000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-019-00630-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,23]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4,1]]}},"alternative-id":["630"],"URL":"https:\/\/doi.org\/10.1007\/s11523-019-00630-y","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.735407983.793577568","asserted-by":"object"}]},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,23]]},"assertion":[{"value":"23 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was funded by Mundipharma (China) Pharmaceutical Co., Ltd.\u00a0Open Access publication of this article was funded by Mundipharma (China) Pharmaceutical Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Stefan Liebscher was an employee of Mundipharma Research GmbH at the time the study was conducted. Guodong Lu and Chunxiao Cai are employees of Mundipharma (China) Pharmaceutical Co., Ltd. Xiaonan Hong, Yuqin Song, Huiqiang Huang, Bing Bai, Huilai Zhang, Xiaoyan Ke, Yuankai Shi, and Jun Zhu declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}